chronic fatigue syndrome: a medical condition characterized by long-term fatigue and other symptoms that limit a person's ability to carry out ordinary daily activities.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
364 |
4. Check minimum number of eventsNone |
364 |
5. Include endpointsNone |
364 |
6. Filter based on genotype QC (FinnGen only) |
334 |
Control definitions (FinnGen only)
- Control exclude
- G6_OTHNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G93
- Name in latin
- Syndroma lassitudinis postvirale
Similar endpoints
↥List of similar endpoints to
Postviral fatigue syndrome
based on the number of shared cases.
Similar with more cases:
- Cerebral cysts
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1622 | 1089 | 525 |
| Only index persons | 1588 | 1074 | 514 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.01 |
| Only index persons | 0.03 | 0.04 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 34.76 | 35.80 | 32.61 |
| Only index persons | 34.81 | 35.74 | 32.86 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 334 | 266 | 68 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.03 |
| Median age at first event (years) | 39.94 | 40.16 | 39.09 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 348
- Matched controls
- 3480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G93.3
ICD-10 Finland
Postviral fatigue syndrome
+∞
307.7
348
8
R53
ICD-10 Finland
Malaise and fatigue
10.8
108.0
245
627
R68.88
ICD-10 Finland
Other specified general symptoms and signs, not elsewhere classified.
35.0
78.6
51
17
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
9.0
62.5
90
130
N06AX21
ATC
duloxetine; oral
6.5
55.9
119
259
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
10.5
55.4
67
77
N06AX12
ATC
bupropion; oral
6.6
55.0
111
229
U09.9
ICD-10 Finland
Post COVID-19 condition, unspecified
25.7
54.4
39
17
M79.7
ICD-10 Finland
Fibromyalgia
10.5
52.2
63
72
A04
ICPC
Weakness/tiredness general
5.6
51.9
140
375
N06AX16
ATC
venlafaxine; oral
5.6
51.4
137
363
N04BC05
ATC
pramipexole; oral
9.3
47.5
63
81
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
5.5
46.2
118
298
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
8.1
44.1
66
98
TAB00
NOMESCO Finland
Lumbar puncture
9.0
43.9
59
77
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
8.7
42.0
58
78
F48.0
ICD-10 Finland
Neurasthenia
238.0
41.9
42
*
M35.7
ICD-10 Finland
Hypermobility syndrome
13.5
41.8
41
34
IDY03
NOMESCO Finland
Systematic individual therapy, cognitive-behavioural
6.7
41.3
75
137
Z01.8
ICD-10 Finland
Other specified special examinations
4.6
41.2
142
453
XA800
NOMESCO Finland
Neuropsychological investigation
7.9
36.8
55
81
N03AX12
ATC
[U] gabapentin; oral
4.8
35.0
97
257
G47.3
ICD-10 Finland
Sleep apnoea
4.3
34.3
119
375
F33.11
ICD-10 Finland
Recurrent depression, moderate episode of somatic syndrome
8.7
34.0
46
60
C07AB07
ATC
bisoprolol; oral
3.9
33.5
160
629
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
5.4
32.0
72
159
L28
ICPC
Limited function/disability (L)
4.9
31.8
84
213
A28
ICPC
Limited function/disability NOS
6.1
31.3
61
118
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
8.2
30.4
43
59
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
5.7
29.9
63
131
R42
ICD-10 Finland
Dizziness and giddiness
4.1
29.3
104
329
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.0
29.0
73
177
N03AX16
ATC
[U] pregabalin
3.9
29.0
112
376
R4110
NOMESCO Finland
Physiotherapy
3.6
28.2
133
509
R50.9
ICD-10 Finland
Fever, unspecified
3.9
27.8
104
340
R51.80
ICD-10 Finland
Headache
3.6
27.5
127
478
R03DC03
ATC
montelukast; oral
3.7
27.3
115
407
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
8.0
27.3
39
54
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
7.3
27.0
42
64
H02AB09
ATC
hydrocortisone; systemic
11.2
26.6
29
28
N06AX26
ATC
vortioxetine; oral
4.4
25.8
75
203
G90.8
ICD-10 Finland
Other disorders of autonomic nervous system
+∞
25.3
24
*
N06AX11
ATC
mirtazapine; oral
3.2
25.1
177
853
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
9.4
24.9
31
36
C07AA05
ATC
propranolol; systemic
3.3
24.7
134
552
M79.0
ICD-10 Finland
Rheumatism, unspecified
8.6
24.7
33
42
Q79.6
ICD-10 Finland
Ehlers-Danlos syndrome
58.3
23.4
27
5
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.5
23.3
103
372
N04BC09
ATC
rotigotine; transdermal
70.0
23.2
26
*
R06.0
ICD-10 Finland
Dyspnoea
3.3
23.0
123
500
H02AB06
ATC
prednisolone; systemic
3.0
22.5
196
1046
XF404
NOMESCO Finland
Ambulatory ECG
6.5
22.2
38
64
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
5.0
22.1
52
118
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.2
22.0
115
459
G43.3
ICD-10 Finland
Complicated migraine
7.1
21.7
34
52
N05BA04
ATC
oxazepam; oral
3.1
21.7
135
596
ZY010
NOMESCO Finland
Hospital outpatient
4.6
21.6
57
142
N06AX22
ATC
agomelatine; oral
6.8
21.4
35
56
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
5.6
21.3
43
85
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
21.1
156
754
N06AB04
ATC
citalopram; systemic
3.2
21.0
107
419
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
222.8
20.8
21
*
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
4.8
20.5
51
121
A01
ICPC
Pain general/multiple sites
4.2
20.4
62
172
N05AH04
ATC
quetiapine; oral
3.1
20.4
119
504
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
4.1
20.2
63
178
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
7.1
19.9
31
47
A02BA02
ATC
ranitidine; systemic
3.7
19.7
74
238
Z2445
NOMESCO Finland
Psychologist
5.0
19.3
45
101
G43.9
ICD-10 Finland
Migraine, unspecified
3.7
19.2
70
221
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
5.6
19.1
38
74
A02BC05
ATC
esomeprazole; systemic
2.8
19.0
166
865
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.2
18.8
55
148
H03AA01
ATC
levothyroxine sodium; systemic
2.9
18.7
117
511
N02BF02
ATC
pregabalin; oral
4.8
18.7
46
108
C01CA24
ATC
epinephrine; parenteral
4.0
18.6
58
164
N06BA07
ATC
modafinil; oral
46.7
18.5
22
5
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.0
18.3
42
93
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
4.0
18.2
58
166
F32.1
ICD-10 Finland
Moderate depressive episode
3.6
18.0
68
219
Z2446
NOMESCO Finland
Social worker
4.4
17.9
49
125
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
3.3
17.6
78
278
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
3.5
17.4
71
240
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
4.0
17.0
53
149
N06CA01
ATC
amitriptyline and psycholeptics; systemic
4.1
16.8
51
141
UJF30
NOMESCO Finland
Ileoscopy through colon
3.9
16.7
54
156
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
4.2
16.7
49
132
R03AC02
ATC
salbutamol; inhalant
2.8
16.6
248
1646
XF402
NOMESCO Finland
ECG with work load test
5.4
16.6
34
68
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.6
16.5
151
792
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
3.5
16.5
64
209
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.3
16.5
46
119
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
5.7
16.4
32
61
A02BC02
ATC
pantoprazole; systemic
2.7
16.3
246
1635
R00.2
ICD-10 Finland
Palpitations
3.6
16.1
61
196
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.8
16.1
111
505
R00.0
ICD-10 Finland
Tachycardia, unspecified
5.0
15.8
36
79
J45.9
ICD-10 Finland
Asthma, unspecified
2.9
15.7
89
364
B03BA03
ATC
hydroxocobalamin; parenteral
6.6
15.7
26
42
N03AX11
ATC
topiramate; oral
5.4
15.6
32
64
F45.4
ICD-10 Finland
Persistent somatoform pain disorder
12.1
15.6
28
25
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.1
15.6
75
280
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
4.3
15.5
43
111
SHA02
NOMESCO Finland
Stomatognathic treatment, basic
3.3
15.3
66
230
A03FA01
ATC
metoclopramide; systemic, rectal
2.8
15.3
100
441
N06AG02
ATC
moclobemide; oral
6.1
15.2
27
47
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
5.1
15.0
33
70
N06BA04
ATC
methylphenidate; oral
3.7
14.9
52
158
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
14.6
64
225
F41.1
ICD-10 Finland
Generalized anxiety disorder
3.3
14.6
62
214
SPAT1215
SPAT
Assessment of need for medical rehabilitation
6.3
14.5
25
42
N06AB03
ATC
fluoxetine; oral
3.2
14.5
66
238
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.5
14.5
55
177
XQ800
NOMESCO Finland
Prick test
3.6
14.2
52
163
K30
ICD-10 Finland
Functional dyspepsia
3.1
14.1
66
241
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.4
14.1
177
1054
N17
ICPC
Vertigo/dizziness
3.3
14.0
60
208
F43.1
ICD-10 Finland
Post-traumatic stress disorder
4.2
13.9
39
101
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.7
13.7
95
429
N06AB06
ATC
sertraline; oral
2.8
13.7
81
338
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
5.2
13.6
29
60
R52.2
ICD-10 Finland
Other chronic pain
5.2
13.6
29
60
R52.9
ICD-10 Finland
Pain, unspecified
3.3
13.5
58
201
N04BD01
ATC
selegiline; oral
27.0
13.5
18
7
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.9
13.3
41
114
R11
ICD-10 Finland
Nausea and vomiting
3.3
13.3
56
192
SPAT1229
SPAT
Assessment of need for aid
6.2
13.2
23
39
F34.1
ICD-10 Finland
Dysthymia
4.4
13.2
35
87
M79.1
ICD-10 Finland
Myalgia
2.6
13.0
92
419
N06AA09
ATC
amitriptyline; systemic
3.9
13.0
40
111
R5140
NOMESCO Finland
Monitoring the use of the aid
3.6
12.8
45
137
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
6.3
12.8
22
37
Z02.7
ICD-10 Finland
Issue of medical certificate
3.5
12.7
47
148
M03BX01
ATC
baclofen; systemic
10.7
12.7
24
24
G43.8
ICD-10 Finland
Other migraine
5.9
12.6
23
41
N06AB10
ATC
escitalopram; oral
2.4
12.6
124
658
G44.2
ICD-10 Finland
Tension-type headache
2.6
12.5
86
386
ICB03
NOMESCO Finland
Psychiatric treatment plan, monitoring
5.7
12.5
24
45
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.6
12.5
31
73
N03AE01
ATC
clonazepam; systemic
4.6
12.5
31
73
M54.2
ICD-10 Finland
Cervicalgia
3.2
12.4
55
194
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
3.9
12.4
38
105
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
4.2
12.4
35
91
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.6
12.4
87
394
XKD00
NOMESCO Finland
Uroflowmetry
4.8
12.4
29
65
N02AX02
ATC
tramadol; systemic, rectal
2.3
12.4
148
852
R20.2
ICD-10 Finland
Paraesthesia of skin
3.4
12.2
48
157
R4120
NOMESCO Finland
Occupational therapy
3.8
12.2
39
111
R96
ICPC
Asthma
3.5
12.2
46
147
N28
ICPC
Limited function/disability (N)
22.2
12.1
17
8
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
6.0
12.1
22
39
3007
Kela drug reimbursment
Erenumab and fremanezumab
6.0
12.1
22
39
F51.0
ICD-10 Finland
Nonorganic insomnia
2.4
11.9
113
587
R03BA08
ATC
ciclesonide; inhalant
3.3
11.8
49
166
J01MA02
ATC
ciprofloxacin; systemic
2.3
11.7
126
691
OAB93, ,
SPAT
2.9
11.6
60
231
G47.8
ICD-10 Finland
Other sleep disorders
5.1
11.6
25
52
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
2.8
11.5
65
263
Z71.8
ICD-10 Finland
Other specified counselling
2.2
11.5
168
1041
SHB00
NOMESCO Finland
Preparing and fitting the occlusal splint in the mouth
2.5
11.4
83
382
N05CF02
ATC
zolpidem; oral
2.6
11.3
80
362
H04.10
ICD-10 Finland
Dry eye syndrome
2.8
11.3
63
253
IGY99
NOMESCO Finland
Other psychiatric treatment contact
4.5
11.2
28
66
Z3231
NOMESCO Finland
Registered nurse
2.3
11.2
110
578
J01FA09
ATC
clarithromycin; systemic
2.2
11.2
139
806
AA1BG, ,
SPAT
6.0
11.1
20
35
Z3226
NOMESCO Finland
Physiotherapist
2.6
11.1
74
325
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.8
11.1
65
268
M25.5
ICD-10 Finland
Pain in joint
2.2
11.0
152
918
J31.0
ICD-10 Finland
Chronic rhinitis
2.9
10.9
56
215
I49.9
ICD-10 Finland
Cardiac arrhythmia, unspecified
2.7
10.9
67
283
H02AA02
ATC
fludrocortisone; oral
61.9
10.7
12
*
F60.5
ICD-10 Finland
Anankastic personality disorder
11.7
10.7
19
17
R1240
NOMESCO Finland
Social assessment of need and possibilities of rehabilitation
11.7
10.7
19
17
IBA04
NOMESCO Finland
Extensive initial psychiatric evaluation
5.3
10.7
22
44
R13
ICD-10 Finland
Dysphagia
4.1
10.6
30
78
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
2.4
10.6
86
415
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.0
10.6
50
183
AA1AD
NOMESCO Finland
CT of head and brain
2.5
10.5
75
340
N02CC03
ATC
zolmitriptan; nasal, oral
3.2
10.5
45
155
J01AA02
ATC
doxycycline; systemic
2.4
10.5
267
2027
R4110, ,
SPAT
2.9
10.4
53
202
U09
ICD-10 Finland
Post COVID-19 condition
11.1
10.4
19
18
K58.9
ICD-10 Finland
Irritable bowel syndrome without diarrhoea
5.0
10.4
23
49
J45.0
ICD-10 Finland
Predominantly allergic asthma
2.9
10.3
54
209
N02BF01
ATC
gabapentin; oral
3.0
10.3
49
180
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
4.0
10.3
30
80
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
3.9
10.2
31
85
R03BA05
ATC
fluticasone; inhalant
2.4
10.2
88
436
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
10.5
10.1
19
19
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.1
10.1
133
781
K07.60
ICD-10 Finland
Snapping jaw
3.1
10.1
44
153
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
15.2
10.1
16
11
R02
ICPC
Shortness of breath/dyspnoea
2.8
10.0
55
219
R4190
NOMESCO Finland
Nutritional therapy
3.9
9.9
30
82
WX723
NOMESCO Finland
CPAP therapy
4.8
9.9
23
51
N05AB03
ATC
perphenazine; systemic, rectal
5.1
9.9
21
43
N07AA02
ATC
pyridostigmine; systemic
20.8
9.9
14
7
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
9.7
75
352
G44.8
ICD-10 Finland
Other specified headache syndromes
8.8
9.7
20
24
G50.1
ICD-10 Finland
Atypical facial pain
10.5
9.6
18
18
N06AX03
ATC
mianserin; oral
4.3
9.6
25
61
ZXD31
NOMESCO Finland
Major difficulties in performing procedure
4.3
9.6
25
61
UJF32
NOMESCO Finland
Coloscopy
2.4
9.6
75
354
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.2
9.5
98
521
R06AE07
ATC
cetirizine; oral
2.0
9.5
188
1276
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
4.2
9.5
26
66
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
5.4
9.5
19
37
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
31.0
9.5
12
*
N05CF01
ATC
zopiclone; oral
2.2
9.4
106
584
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
4.1
9.3
26
67
A06AC01
ATC
ispaghula (psylla seeds); oral
2.3
9.3
88
451
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
3.6
9.3
31
91
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
3.6
9.3
32
96
G47.9
ICD-10 Finland
Sleep disorder, unspecified
4.2
9.2
25
63
F33.1
ICD-10 Finland
Recurrent depressive disorder, current episode moderate
3.5
9.1
32
97
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
2.3
9.1
80
397
G54.0
ICD-10 Finland
Brachial plexus disorders
4.4
9.1
23
55
T78.4
ICD-10 Finland
Allergy, unspecified
3.6
9.0
31
93
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.0
8.8
137
849
ZXY01
NOMESCO Finland
Chief Physician, Head of Department or Deputy Chief Physician
8.0
8.8
19
25
Z01.9
ICD-10 Finland
Special examination, unspecified
3.5
8.7
31
95
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.3
8.7
82
419
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
12.0
8.7
15
13
P29
ICPC
Psychological sympt/compl other
2.5
8.6
61
274
R01AD05
ATC
budesonide; nasal
3.1
8.6
38
133
ZYC01
NOMESCO Finland
Remote contact by phone
3.2
8.6
36
122
R07.4
ICD-10 Finland
Chest pain, unspecified
2.2
8.6
85
442
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.6
8.6
29
86
M01AH01
ATC
celecoxib; oral
2.6
8.5
54
230
L19
ICPC
Muscle symptom/complaint NOS
4.5
8.5
21
49
M03BC01
ATC
orphenadrine (citrate); systemic
2.1
8.5
105
596
N05BA01
ATC
diazepam; systemic, rectal
2.7
8.5
48
193
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
8.5
144
916
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.6
8.5
51
212
R06.5
ICD-10 Finland
Mouth breathing
2.9
8.4
41
152
F41.09
ICD-10 Finland
UNS Panic Syndrome
3.7
8.4
27
77
SPAT1216
SPAT
Assessment of functional ability
3.0
8.3
38
136
R51.81
ICD-10 Finland
Facial pain NOS
6.8
8.3
20
31
M01AE02
ATC
naproxen; oral, rectal
2.0
8.3
229
1714
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
4.6
8.3
20
46
C09CA06
ATC
candesartan; oral
2.2
8.2
84
442
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
8.2
86
458
K59.09
ICD-10 Finland
Constipation, unspecified
3.8
8.2
25
69
R07.0
ICD-10 Finland
Pain in throat
2.7
8.2
48
197
D01
ICPC
Abdominal pain/cramps general
2.3
8.2
69
336
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
17.7
8.1
12
7
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
9.3
8.1
16
18
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.2
8.1
74
373
J45.1
ICD-10 Finland
Nonallergic asthma
3.3
8.0
31
100
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.9
8.0
158
1052
N03AX09
ATC
lamotrigine; oral
3.0
8.0
37
133
N02CC05
ATC
almotriptan; oral
3.2
8.0
33
111
N06AX05
ATC
trazodone; oral
6.4
8.0
20
33
R06AX13
ATC
loratadine; oral
2.2
8.0
76
389
R01AD12
ATC
fluticasone furoate; nasal
1.9
8.0
154
1019
Z2221
NOMESCO Finland
Medical doctor
2.0
7.9
118
714
IBA01, ,
SPAT
4.2
7.9
21
52
U08.9
ICD-10 Finland
Personal history of COVID-19, unspecified
11.2
7.9
14
13
P01
ICPC
Feeling anxious/nervous/tense
2.1
7.8
98
557
N92.6
ICD-10 Finland
Irregular menstruation, unspecified
2.5
7.8
52
227
F41.8
ICD-10 Finland
Other specified anxiety disorders
3.2
7.8
31
102
S13.4
ICD-10 Finland
Sprain and strain of cervical spine
3.2
7.8
31
102
LCA06
NOMESCO Finland
Biopsy of endometrium
2.3
7.8
63
301
A11
ICPC
Chest pain NOS
3.3
7.7
29
92
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
3.8
7.7
24
67
M01AC06
ATC
meloxicam; systemic, rectal
2.0
7.7
110
655
A29
ICPC
General symptom/complaint other
2.5
7.7
53
235
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
3.6
7.7
26
77
F33.00
ICD-10 Finland
Recurrent depression, mild episode without somatic syndrome
4.0
7.6
22
58
N99
ICPC
Neurological disease other
18.9
7.6
11
6
J02AC01
ATC
fluconazole; systemic
1.9
7.6
175
1219
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
9.2
7.6
15
17
A02BA03
ATC
famotidine; systemic
10.4
7.6
14
14
R06AX26
ATC
fexofenadine; oral
2.7
7.6
43
173
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
7.6
127
798
R03AK11
ATC
formoterol and fluticasone; inhalant
6.7
7.5
18
28
Z3229
NOMESCO Finland
Other healthcare associate professional
3.2
7.5
30
99
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.3
7.4
28
89
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
13.8
7.4
12
9
K59.1
ICD-10 Finland
Functional diarrhoea
3.6
7.4
25
74
G44.0
ICD-10 Finland
Cluster headache syndrome
7.1
7.4
17
25
N80.0
ICD-10 Finland
Endometriosis of uterus
4.3
7.4
19
46
N05BE01
ATC
buspirone; oral
4.3
7.4
19
46
P03
ICPC
Feeling depressed
2.2
7.4
74
386
E61.1
ICD-10 Finland
Iron deficiency
3.2
7.3
29
95
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
7.3
7
*
I49.8
ICD-10 Finland
Other specified cardiac arrhythmias
4.5
7.3
18
42
P76
ICPC
Depressive disorder
2.5
7.3
50
221
J45
ICD-10 Finland
Asthma
2.5
7.3
50
221
N06AB05
ATC
paroxetine; oral
3.0
7.3
32
112
F51.9
ICD-10 Finland
Nonorganic sleep disorder, unspecified
4.1
7.3
20
51
A02BC04
ATC
rabeprazole; oral
2.6
7.3
43
177
G04CA01
ATC
alfuzosin; oral
4.7
7.3
17
38
C10AC01
ATC
colestyramine; oral
4.7
7.3
17
38
P01AB01
ATC
metronidazole; oral, rectal
1.9
7.2
153
1034
NXL00
NOMESCO Finland
Biopsy of muscle
30.7
7.2
9
*
L99
ICPC
Musculoskeletal disease other
5.8
7.2
19
34
JN3AD
NOMESCO Finland
Abdominal CT examination
2.6
7.1
45
191
Z31.5
ICD-10 Finland
Genetic counselling
2.8
7.1
38
148
F33.01
ICD-10 Finland
Recurrent depression, mild episode of somatic syndrome
12.4
7.1
12
10
SPAT1301
SPAT
No procedures
2.0
7.1
105
630
M47.80
ICD-10 Finland
Other spondylosis, multiple sites in spine
9.1
7.1
14
16
N05AX12
ATC
aripiprazole; systemic
2.9
7.1
35
131
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.7
7.1
39
155
M79.6
ICD-10 Finland
Pain in limb
1.8
7.0
165
1148
IGY02
NOMESCO Finland
Psychiatric monitoring contact
3.1
7.0
30
103
M54.5
ICD-10 Finland
Low back pain
1.8
7.0
150
1014
N94.1
ICD-10 Finland
Dyspareunia
6.6
7.0
17
27
ICB02
NOMESCO Finland
Psychiatric treatment plan, extended/prolonged
6.1
7.0
18
31
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
2.6
7.0
42
174
E0000UV, ,
ATC
1.8
7.0
160
1106
F32.00
ICD-10 Finland
Mild depressive episode without somatic syndrome
3.1
6.9
30
104
SHA03
NOMESCO Finland
Stomatognathic treatment, demanding
3.3
6.9
26
83
R4120, ,
SPAT
11.2
6.8
12
11
R29
ICPC
Respiratory symptom/complaint other
2.7
6.8
38
152
R05
ICD-10 Finland
Cough
2.0
6.8
85
481
A03
ICPC
Fever
2.0
6.8
93
544
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.9
6.7
32
117
R01AD08
ATC
fluticasone; nasal
1.9
6.7
122
781
J05AB11
ATC
valaciclovir; oral
2.2
6.7
62
312
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.6
6.7
39
159
T91
ICPC
Vitamin/nutritional deficiency
23.0
6.7
9
*
IBZ02
NOMESCO Finland
Somatic assessment of psychiatric patient
23.0
6.7
9
*
F33
ICD-10 Finland
Recurrent depressive disorder
3.7
6.7
21
59
H53.2
ICD-10 Finland
Diplopia
6.1
6.7
17
29
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
2.4
6.7
46
204
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
3.2
6.7
27
90
N06BA12
ATC
lisdexamfetamine; oral
4.0
6.6
19
50
ZX120
NOMESCO Finland
Intravenous
2.8
6.6
34
130
OAB74
NOMESCO Finland
Nutritional guidance related to treatment and rehabilitation for medical condition
9.0
6.6
13
15
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
7.1
6.6
15
22
N29
ICPC
Neurological sympt/complt other
7.1
6.6
15
22
N06AX17
ATC
milnacipran; oral
10.3
6.6
12
12
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.4
6.6
24
75
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.2
6.5
60
301
UJF92
NOMESCO Finland
Capsular endoscopy
5.9
6.5
17
30
R06AX22
ATC
ebastine; oral
2.0
6.5
81
457
F33.4
ICD-10 Finland
Recurrent depressive disorder, currently in remission
3.2
6.5
25
81
R51
ICD-10 Finland
Headache
2.6
6.4
38
156
ICB07, ,
NOMESCO Finland
71.1
6.4
7
*
A02BC01
ATC
omeprazole; systemic
2.0
6.4
86
497
R21
ICPC
Throat symptom/complaint
1.8
6.4
131
868
N02CD03
ATC
fremanezumab; systemic
5.7
6.4
17
31
M03AX01
ATC
botulinum toxin; parenteral
6.2
6.4
16
27
LX1AE
NOMESCO Finland
Gynecological ultrasound examination as part of clinical examination
2.1
6.4
68
362
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
3.0
6.4
28
98
A07AA02
ATC
nystatin; oral
4.0
6.3
18
47
F29
ICPC
Eye symptom/complaint other
2.3
6.3
48
222
R03AK10
ATC
vilanterol and fluticasone furoate; inhalant
3.1
6.3
27
93
R68.81
ICD-10 Finland
A constant or recurrent sensitivity to experience symptoms and signs in relation to common factors in the environment, not elsewhere classified.
18.4
6.3
9
5
P99
ICPC
Psychological disorders other
3.3
6.3
24
77
R1210
NOMESCO Finland
Medical assessment of need and possibilities to rehabilitation
7.2
6.3
14
20
N89
ICPC
Migraine
2.7
6.3
35
140
H02
ICPC
Hearing complaint
2.7
6.2
34
134
R03AC12
ATC
salmeterol; inhalant
4.1
6.2
17
43
F90.0
ICD-10 Finland
Disturbance of activity and attention
2.5
6.2
42
184
OAA68, ,
SPAT
5.9
6.2
16
28
A04AA01
ATC
ondansetron; systemic, rectal
2.8
6.2
31
117
D09
ICPC
Nausea
2.7
6.2
34
135
R33
ICD-10 Finland
Retention of urine
4.3
6.2
16
39
J01FF01
ATC
clindamycin; systemic
1.9
6.1
93
560
DM1AI
NOMESCO Finland
Cone beam CT of paranasal sinus
3.7
6.1
19
53
N06AX18
ATC
reboxetine; oral
12.8
6.1
10
8
A99
ICPC
Disease/condition unspecnature/site
2.5
6.1
40
173
R06.4
ICD-10 Finland
Hyperventilation
6.9
6.1
14
21
N06AA10
ATC
nortriptyline; systemic
5.4
6.1
17
33
S01GX01
ATC
cromoglicic acid; ophthalmic
1.9
6.1
101
626
R69
ICD-10 Finland
Unknown and unspecified causes of morbidity
6.2
6.1
15
25
M01AE03
ATC
ketoprofen; systemic, rectal
1.9
6.0
103
644
A02BC03
ATC
lansoprazole; oral
1.9
6.0
84
492
H02AB07
ATC
prednisone; oral
2.3
6.0
45
207
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
204
295
15.30
152.93
2.6
1.9
386.22
376.44
nmol/l
0.29
195
278
171
230
13.65
133.00
2.9
2.3
30.62
17.63
au/ml
—
9
29
83
84
12.66
75.92
1.3
1.4
258.05
170.03
u/ml
2.34
59
51
118
236
7.05
60.85
3.0
2.5
10.02
10.31
g/l
0.46
107
227
249
1020
6.07
56.20
2.4
1.8
99.58
96.28
pmol/l
0.49
145
586
128
300
6.17
55.54
2.8
2.4
28.52
24.14
%
3.36
121
281
141
367
5.78
54.35
3.1
2.3
16.67
14.33
umol/l
3.74
133
343
132
334
5.76
52.29
3.0
2.3
2.45
2.46
g/l
0.07
127
306
237
983
5.42
51.14
5.1
6.5
1.22
1.22
mmol/l
0.08
229
919
253
1135
5.50
48.66
5.7
6.5
1.22
1.21
mmol/l
0.13
225
994
271
1313
5.81
46.54
3.5
2.6
76.89
72.58
nmol/l
1.73
263
1248
76
129
7.26
45.04
1.9
1.3
—
—
—
0
0
145
458
4.71
42.84
1.8
1.6
453.98
64048035.28
pmol/l
1.04
137
420
41
36
12.78
40.31
1.7
1.4
23.04
30.30
ng/l
0.33
41
36
169
631
4.26
39.31
1.8
1.5
20.75
20.85
nmol/l
0.02
159
577
220
997
4.28
38.73
3.9
4.8
38.27
37.54
g/l
1.54
210
956
121
358
4.65
38.35
2.9
3.6
0.84
0.82
mmol/l
1.39
113
342
51
66
8.88
38.03
1.3
1.8
13.51
75.20
e6/l
0.90
41
51
196
836
4.08
37.25
2.3
2.8
2.33
2.35
mmol/l
1.46
184
786
50
65
8.82
37.12
1.2
1.8
1.03
16.52
e6/l
0.79
38
48
35
27
14.30
37.10
1.2
1.2
23.70
29.60
mg/l
0.59
30
21
113
331
4.57
36.04
1.7
1.3
82.72
149.11
u/ml
1.68
45
144
64
114
6.65
35.86
1.8
1.1
3.63
4.55
—
9
22
302
1785
6.23
35.78
6.0
3.3
82.79
69.02
ug/l
1.19
296
1719
291
1712
5.27
33.52
8.8
9.6
3.84
3.92
e9/l
0.29
269
1511
81
195
5.11
32.68
2.5
4.2
188.71
235.64
u/l
4.07
75
195
35
36
10.70
30.83
1.5
2.0
5.07
5.12
kpa
0.12
35
36
33
33
10.94
29.61
1.1
1.1
—
—
—
0
0
94
277
4.28
29.18
1.6
1.3
131.21
174.28
u/ml
0.28
88
252
251
1431
3.71
27.68
4.5
4.9
5.75
6.26
mmol/l
6.75
235
1290
32
34
10.26
27.48
1.1
1.1
—
—
—
0
0
157
676
3.41
27.45
3.1
2.5
0.09
0.28
e6/l
3.13
121
485
182
858
3.35
27.37
2.2
1.4
1.87
2.10
g/l
2.04
136
575
134
540
3.41
25.81
2.2
2.9
40.58
85.80
ug/g
6.26
101
429
32
39
8.93
24.77
1.6
1.3
0.15
0.15
nmol/l
0.01
26
28
63
155
4.74
24.40
1.9
2.2
2.36
5.29
iu/ml
1.46
18
28
91
295
3.82
24.36
1.8
1.5
1163.51
1089.24
nmol/l
0.31
73
237
29
32
9.80
24.18
1.0
1.1
—
—
—
0
0
125
509
3.27
23.31
2.6
2.3
4.29
9.59
e6/l
2.43
114
461
109
409
3.42
23.23
2.1
2.1
2.39
2.41
mmol/l
0.59
93
363
162
783
3.00
22.19
3.6
2.7
25.63
20.30
ng/l
0.16
59
327
151
713
2.97
21.42
3.2
2.3
2.14
2.59
mg/l
3.69
135
631
101
382
3.32
21.02
2.6
2.4
3.10
3.74
e6/l
0.26
56
178
225
1332
2.95
20.65
5.2
5.7
9.40
10.18
umol/l
1.08
215
1278
183
972
2.86
20.65
1.7
1.4
2.08
1.90
u/ml
0.04
63
279
247
1547
3.06
20.25
4.4
3.1
0.07
4.67
estimate
0.49
71
323
248
1559
3.06
20.15
4.4
3.2
0.00
0.00
estimate
-0.00
73
311
245
1539
3.00
19.76
4.3
3.1
0.00
0.00
estimate
0.50
72
319
52
131
4.49
19.39
2.0
9.9
25.20
25.04
mmol/l
0.14
52
131
31
21
16.08
19.32
1.3
1.1
0.48
0.56
ratio
1.64
21
11
40
83
5.32
18.76
1.6
1.1
7.58
16.38
au/ml
1.02
13
33
328
2508
6.36
18.41
7.8
4.5
14.49
14.26
pmol/l
1.17
323
2378
190
1081
2.67
17.98
3.5
3.2
23.86
27.66
u/l
2.10
185
1042
98
397
3.04
17.85
2.3
3.1
683.27
440.54
ng/l
0.24
74
321
339
2852
8.29
17.23
9.5
5.3
1.61
1.71
mu/l
1.30
334
2748
55
158
3.95
17.17
2.6
1.8
—
—
—
0
0
27
18
16.15
16.96
1.8
3.3
356.59
429.00
u/ml
0.56
27
18
24
12
21.37
16.66
1.5
1.1
119.25
185.17
mmol/24h
1.91
24
12
34
68
5.43
16.56
1.3
1.1
1.21
1.66
—
8
19
137
691
2.62
16.21
2.3
2.0
0.36
0.78
mg/l
3.98
92
515
137
699
2.58
15.74
1.5
1.3
363.17
22.64
iu/ml
0.49
29
201
27
25
11.61
14.77
1.1
1.1
—
—
—
0
0
27
49
5.89
14.54
1.2
2.3
2.73
2.72
g/l
0.01
27
49
165
944
2.42
14.53
3.5
2.5
0.78
0.03
estimate
0.47
64
267
146
795
2.44
14.31
4.3
3.2
0.00
0.01
estimate
1.08
73
318
61
211
3.29
14.31
2.4
2.9
0.25
0.23
g/l
1.47
56
204
194
1199
2.40
14.25
4.0
2.9
0.00
0.03
estimate
0.96
63
276
27
50
5.77
14.24
1.2
2.3
4.74
4.47
g/l
0.19
27
50
27
50
5.77
14.24
1.2
2.3
3.77
3.48
g/l
0.26
27
50
27
50
5.77
14.24
1.2
2.3
6.61
6.87
g/l
0.43
27
50
133
699
2.46
14.04
3.5
2.9
1.02
1.02
kg/l
2.14
98
452
22
34
6.84
13.81
1.1
1.3
—
—
—
0
0
322
2571
4.38
13.71
5.4
4.3
35.57
36.99
mmol/mol
3.22
317
2483
124
644
2.44
13.32
1.5
1.3
1.31
9.41
u/ml
2.22
48
271
88
393
2.66
12.95
1.7
1.4
22.02
21.77
iu/l
0.03
77
342
86
380
2.68
12.92
3.3
2.8
106.72
249.86
ng/l
0.83
29
193
21
34
6.51
12.62
1.1
1.2
—
—
—
0
0
30
69
4.66
12.42
1.4
1.4
341.50
354.22
ug/g
0.08
14
38
68
286
2.71
11.14
2.2
2.9
29.57
29.92
s
0.26
68
281
86
412
2.44
10.75
2.7
2.3
0.52
0.84
e6/l
1.04
44
206
21
40
5.52
10.72
1.2
2.3
9.43
10.02
g/l
0.37
21
40
22
26
8.95
10.71
1.4
1.6
—
—
—
0
0
38
120
3.43
10.21
1.1
1.1
2.40
6.77
u/ml
1.50
23
69
49
185
2.92
9.78
2.0
1.8
3.99
3.26
mg/l
0.30
39
129
20
40
5.24
9.69
1.2
2.3
0.00
0.00
g/l
-0.00
20
35
48
182
2.90
9.50
1.4
1.4
—
—
—
0
0
339
3048
5.34
9.48
20.9
10.8
15.29
19.25
mg/l
1.82
287
2399
17
16
11.10
9.39
1.8
2.4
2.28
1.91
nmol/l
0.21
17
16
46
172
2.93
9.33
1.4
1.4
11.75
10.32
u/l
0.20
35
139
326
2778
3.74
9.30
15.8
8.9
96.61
95.60
ml/min/173m2
0.47
306
2489
48
185
2.85
9.22
3.2
2.1
13.58
12.74
nmol/l
0.26
43
177
46
179
2.81
8.67
4.2
5.8
2.15
1.60
mmol/l
0.62
40
153
21
33
6.70
8.62
1.1
1.2
—
—
—
0
0
21
33
6.70
8.62
1.1
1.2
—
—
—
0
0
21
33
6.70
8.62
1.1
1.2
—
—
—
0
0
20
31
6.78
8.31
1.2
1.2
—
—
—
0
0
17
21
8.45
8.18
1.2
1.0
0.94
1.02
u/l
—
7
10
20
32
6.56
8.14
2.4
5.5
151.06
48.27
u/ml
—
5
11
20
47
4.45
8.05
1.2
1.1
8.54
12.12
u/ml
—
9
26
19
29
6.86
8.00
1.3
2.1
18.81
17.42
%
1.39
19
29
37
134
2.97
7.93
1.5
1.5
0.26
0.36
nmol/l
1.47
31
113
317
2713
2.89
7.87
4.8
3.5
5.50
5.60
mmol/l
0.90
307
2585
34
118
3.09
7.84
3.6
6.9
23.50
24.09
mmol/l
0.47
34
118
12
8
15.47
7.77
1.1
1.0
—
—
—
0
0
22
58
3.98
7.65
2.0
4.5
9.50
8.77
kpa
1.21
22
58
11
6
18.87
7.65
1.2
1.2
—
—
—
0
0
11
6
18.87
7.65
1.2
1.0
—
—
—
0
0
51
226
2.47
7.41
1.9
1.5
—
—
—
0
0
43
179
2.60
7.10
1.4
1.7
0.15
0.27
mg/l
—
6
79
65
330
2.19
6.90
1.9
1.6
—
—
—
0
0
31
110
3.00
6.88
1.8
3.6
1.87
0.97
mmol/l
0.71
21
82
12
12
10.31
6.58
1.1
1.2
67.23
75.42
nmol/24h
0.17
12
12
36
144
2.67
6.43
1.3
1.6
—
—
—
0
0
9
5
18.42
6.29
1.0
1.2
—
—
—
0
0
9
5
18.42
6.29
1.1
1.6
—
—
—
0
0
9
5
18.42
6.29
1.1
1.4
—
—
—
0
0
278
2320
1.99
6.18
4.0
3.2
29.12
33.36
u/l
1.22
273
2251
31
118
2.79
6.08
1.2
1.1
0.80
1.50
u/ml
0.48
15
57
49
235
2.26
5.94
2.0
1.5
—
—
—
0
0
54
270
2.18
5.92
3.5
2.4
29.96
31.96
u/l
0.21
49
226
22
71
3.24
5.72
1.2
1.3
—
—
—
0
0
18
52
3.60
5.53
1.1
1.5
—
—
—
0
0
18
54
3.46
5.24
2.7
2.2
0.29
1.97
index
—
7
26
94
595
1.79
5.20
2.0
2.3
292.25
305.03
umol/l
0.77
85
561
61
338
1.98
5.08
2.0
2.8
4.30
5.86
umol/l
0.97
50
292
48
244
2.12
5.04
6.5
7.6
104.02
104.75
mmol/l
0.63
48
244
85
527
1.81
5.02
1.8
1.9
1.37
1.32
%
0.44
78
494
148
1072
1.66
5.00
2.2
1.8
—
—
—
0
0
32
139
2.43
4.85
1.2
1.1
0.16
3.13
u/ml
2.89
16
77
23
87
2.76
4.59
1.2
1.1
0.01
0.32
u/ml
—
5
25
26
105
2.60
4.58
1.2
1.0
0.55
3.58
u/ml
1.83
11
46
15
44
3.52
4.52
1.3
2.4
4.82
6.77
pmol/l
1.02
15
44
12
23
5.36
4.49
1.1
1.0
135.42
120.09
pmol/l
0.44
12
23
14
32
4.51
4.49
1.1
2.0
518.00
549.37
e6/l
—
8
24
14
33
4.38
4.37
1.1
1.8
269.25
230.19
e6/l
—
8
26
26
108
2.52
4.34
1.7
1.4
—
—
—
0
0
21
78
2.80
4.33
1.0
1.1
3.01
2.18
eliau/ml
—
7
40
10
17
6.02
4.16
1.1
1.1
—
—
—
0
0
15
48
3.22
3.98
1.3
1.2
—
—
—
0
0
22
89
2.57
3.88
1.7
2.4
205.63
93.42
ng/l
0.34
16
78
8
11
7.41
3.88
1.0
1.0
—
—
—
0
0
14
45
3.20
3.69
1.0
1.1
—
—
—
0
0
27
125
2.26
3.58
1.6
2.4
2.41
4.69
iu/l
—
9
56
11
26
4.33
3.53
1.2
1.1
161.23
172.42
iu/ml
0.07
11
26
15
52
2.97
3.51
1.7
2.3
142.47
133.95
g/l
1.40
15
42
22
94
2.43
3.49
1.2
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
14
5.82
3.36
1.4
1.3
—
—
—
0
0
10
24
4.26
3.22
1.3
1.8
1.84
1.65
mmol/l
—
10
24
8
15
5.43
3.21
1.5
1.3
—
—
—
0
0
21
93
2.34
3.10
1.1
1.2
—
—
—
0
0
54
337
1.71
3.07
2.3
2.1
1301.38
5856.72
u/l
1.86
18
142
120
911
1.48
2.96
2.3
2.2
—
—
—
0
0
14
52
2.76
2.92
1.1
1.3
—
—
—
0
0
27
137
2.05
2.89
2.0
1.8
16.51
6.39
u/ml
—
8
39
24
117
2.13
2.84
1.3
1.5
0.03
0.04
iu/ml
—
9
18
19
85
2.31
2.75
6.4
3.5
48.31
51.94
%
0.23
19
85
16
66
2.49
2.75
1.3
1.3
4.55
3.80
u/ml
0.13
11
30
11
34
3.31
2.75
1.6
3.3
16.61
16.48
mu/l
0.01
11
34
8
19
4.28
2.69
1.8
1.8
—
—
—
0
0
9
24
3.82
2.69
1.3
1.1
53.36
55.21
u/ml
—
9
24
16
67
2.45
2.67
1.3
1.2
2.50
4.22
u/ml
—
8
27
31
171
1.89
2.64
8.4
11.7
1.47
0.88
mmol/l
0.36
23
144
14
312
0.43
2.64
1.4
1.5
—
—
—
0
0
110
838
1.46
2.62
2.2
2.1
—
—
—
0
0
9
25
3.67
2.59
1.0
1.1
2745.22
1521.24
miu/ml
—
9
25
9
25
3.67
2.59
1.7
1.5
—
—
—
0
0
13
50
2.66
2.56
1.5
1.3
—
—
—
0
0
13
50
2.66
2.56
1.5
1.3
—
—
—
0
0
5
7
7.23
2.55
1.0
1.0
—
—
—
0
0
5
7
7.23
2.55
1.2
1.3
—
—
—
0
0
5
7
7.23
2.55
1.0
1.3
—
—
—
0
0
311
2892
1.71
2.48
4.4
3.8
1.46
1.48
mmol/l
0.46
300
2788
17
76
2.30
2.48
1.6
1.6
—
—
—
0
0
31
175
1.85
2.47
2.8
2.2
83.47
81.72
ml/min/173m2
0.10
19
74
16
70
2.35
2.45
1.2
1.1
—
—
—
0
0
11
38
2.96
2.43
1.5
1.3
—
—
—
0
0
11
38
2.96
2.43
1.7
2.1
—
—
—
0
0
144
1166
1.40
2.42
1.9
1.8
1.38
1.39
mmol/l
0.01
127
1062
8
22
3.70
2.38
1.3
1.6
5.02
5.43
mmol/l
—
8
22
311
2899
1.68
2.37
4.6
3.9
4.79
4.79
mmol/l
0.02
301
2804
111
863
1.42
2.34
1.9
1.6
—
—
—
0
0
312
2913
1.69
2.33
4.9
4.1
2.93
2.88
mmol/l
0.54
302
2815
20
99
2.08
2.31
5.1
5.5
0.52
0.60
%
0.62
20
99
12
267
0.43
2.27
1.2
1.5
0.75
0.93
ratio
—
7
171
12
267
0.43
2.27
1.2
1.5
1.13
1.15
ratio
—
7
171
12
267
0.43
2.27
1.2
1.5
1.20
1.12
ratio
—
7
171
36
219
1.72
2.26
6.5
4.1
—
—
—
0
0
12
264
0.44
2.21
1.2
1.5
—
—
—
0
0
5
10
5.05
2.07
1.0
1.0
—
—
—
0
0
7
20
3.55
2.06
1.0
2.1
—
0.99
—
0
6
6
15
4.05
2.04
1.3
1.5
—
—
—
0
0
6
15
4.05
2.04
1.3
1.5
—
—
—
0
0
38
242
1.64
2.03
1.1
1.0
—
—
—
0
0
6
17
3.57
1.84
1.2
1.1
—
—
—
0
0
5
12
4.21
1.83
3.2
3.3
140.40
115.00
%
—
5
12
5
12
4.21
1.83
3.8
3.0
—
—
—
0
0
8
31
2.62
1.67
1.3
1.3
—
—
—
0
0
8
32
2.53
1.60
1.3
1.3
—
—
—
0
0
6
20
3.03
1.58
1.2
1.7
—
—
—
0
0
8
33
2.46
1.54
1.1
1.3
—
—
—
0
0
8
33
2.46
1.54
1.3
1.2
—
—
—
0
0
17
93
1.87
1.54
2.3
1.5
—
—
—
0
0
65
494
1.39
1.53
2.1
1.9
—
—
—
0
0
5
16
3.15
1.44
1.4
1.1
98.18
186.62
pmol/l
—
5
16
9
39
2.34
1.44
1.3
1.4
—
—
—
0
0
11
53
2.11
1.40
1.1
1.4
—
—
—
0
0
75
595
1.33
1.35
2.0
2.1
—
—
—
0
0
12
62
1.97
1.29
1.0
1.1
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
5
18
2.80
1.29
1.0
1.0
117.00
136.78
%
—
5
18
8
35
2.32
1.27
1.3
1.1
—
—
—
0
0
29
196
1.52
1.26
1.7
1.6
—
—
—
0
0
6
25
2.42
1.25
2.0
1.5
54.00
70.36
umol/l
—
6
25
28
189
1.52
1.23
3.3
2.4
—
—
—
0
0
288
2724
1.33
1.22
3.9
3.3
1.23
1.21
mmol/l
0.17
276
2610
8
37
2.19
1.22
1.4
1.1
26.91
34.12
nmol/l
—
8
27
22
142
1.59
1.17
3.9
4.5
2.13
8.83
ug/l
2.09
17
108
7
32
2.21
1.08
1.3
1.3
—
—
—
0
0
7
32
2.21
1.08
1.3
1.3
—
—
—
0
0
7
32
2.21
1.08
1.3
1.3
—
—
—
0
0
24
162
1.52
1.07
1.2
1.4
—
—
—
0
0
7
33
2.14
1.06
1.3
1.2
—
—
—
0
0
7
33
2.14
1.06
1.3
1.2
—
—
—
0
0
5
22
2.29
1.03
1.2
1.1
6.20
7.77
mm/h
—
5
22
13
213
0.60
1.03
1.1
1.1
1.65
1.56
g/l
0.54
13
213
17
108
1.60
0.98
1.4
1.6
—
—
—
0
0
28
200
1.44
0.97
2.1
1.9
22.65
35.84
u/ml
0.69
28
192
10
55
1.84
0.93
1.2
1.5
7.08
7.35
mmol/l
—
10
48
8
42
1.93
0.89
1.1
1.3
—
—
—
0
0
14
216
0.63
0.89
1.1
1.1
0.91
0.89
g/l
0.16
14
216
6
30
2.02
0.87
1.2
1.3
—
—
—
0
0
6
31
1.95
0.85
1.2
2.1
0.94
0.79
e9/l
—
6
31
6
31
1.95
0.85
1.0
2.6
—
—
—
0
0
5
26
1.94
0.71
1.8
1.3
—
—
—
0
0
10
61
1.66
0.69
1.2
1.5
—
—
—
0
0
9
59
1.54
0.69
5.6
3.0
8.00
528.54
u/ml
—
9
52
5
27
1.86
0.68
1.2
1.4
—
—
—
0
0
76
663
1.19
0.63
1.9
2.1
—
—
—
0
0
8
49
1.65
0.62
1.1
1.3
—
—
—
0
0
279
2690
1.19
0.61
5.0
3.9
—
—
—
0
0
9
60
1.51
0.54
1.0
1.4
—
—
—
0
0
66
581
1.17
0.50
3.2
3.9
22.55
10.52
mg/mmol
0.32
41
379
29
236
1.25
0.48
1.2
1.4
—
—
—
0
0
18
141
1.29
0.41
2.6
2.0
0.57
0.65
ug/l
—
10
51
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
5
35
1.43
0.39
1.2
1.5
—
—
—
0
0
23
188
1.24
0.38
2.5
2.7
21.82
21.72
%
—
8
46
6
45
1.34
0.34
2.0
1.6
6.30
7.59
mmol/l
—
6
45
6
90
0.66
0.33
1.3
1.4
—
—
—
0
0
11
83
1.34
0.32
2.1
2.0
—
—
—
0
0
10
77
1.31
0.26
1.8
1.8
—
—
—
0
0
19
162
1.18
0.23
1.2
1.6
73.45
53.61
ug/l
1.19
19
162
19
220
0.86
0.22
1.4
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
14.0
—
38.14
—
0
7
0
13
0.00
0.21
0.0
1.3
—
57.08
—
0
13
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
19
164
1.17
0.21
2.3
1.9
—
—
—
0
0
16
187
0.85
0.20
1.6
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
7
63
1.11
0.17
1.6
1.1
—
—
—
0
0
142
1377
1.05
0.16
2.5
2.7
—
—
estimate
—
0
0
51
535
0.95
0.11
2.4
1.8
3.25
3.33
ratio
0.17
38
410
44
421
1.05
0.08
2.0
1.6
3.16
3.42
mmol/l
0.77
30
295
17
181
0.94
0.05
1.5
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1.43
—
0
5
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
23
230
1.00
-0.00
1.3
1.3
247.00
258.82
miu/ml
—
9
115
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
7.02
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
2.44
—
0
5
0
6
0.00
-0.00
0.0
3.5
—
4.10
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_POSTVIRFAT and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have G6_POSTVIRFAT.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: G6_POSTVIRFAT – Postviral fatigue syndrome
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data